Daclizumab induction and maintenance steroid‐free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Transplant International

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1432-2277.2006.00326.xPMID 16827681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corticosteroid‐free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study

  2005cited by this paper
• Two-dose Daclizumab Induction Therapy in 209 Liver Transplants: A Single-Center Analysis

  2004cited by this paper
• IMPACT OF HEPATITIS C VIRAL INFECTION IN PRIMARY CADAVERIC LIVER ALLOGRAFT VERSUS PRIMARY LIVING-DONOR ALLOGRAFT IN 100 CONSECUTIVE LIVER TRANSPLANT RECIPIENTS RECEIVING TACROLIMUS

  2004cited by this paper
• Double-Blind Comparison of Hepatitis C Histological Recurrence Rate in HCV+ Liver Transplant Recipients Given Basiliximab+Steroids or Basiliximab+Placebo, in addition to Cyclosporine and Azathioprine

  2004cited by this paper
• RESULTS OF LIS2T, A MULTICENTER, RANDOMIZED STUDY COMPARING CYCLOSPORINE MICROEMULSION WITH C2 MONITORING AND TACROLIMUS WITH C0 MONITORING IN DE NOVO LIVER TRANSPLANTATION

  2004influential reference
• Steroid withdrawal at day 14 after liver transplantation: A double‐blind, placebo‐controlled study

  2004influential reference
• Steroid‐free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy

  2004influential reference
• Osteoporosis after liver transplantation

  2003cited by this paper
• Osteoporosis in liver diseases and after liver transplantation.

  2003cited by this paper
• Steroid‐free immunosuppression during and after liver transplantation – a 3‐yr follow‐up report

  2003cited by this paper
• Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1

  2003cited by this paper
• Early steroid withdrawal after liver transplantation: The canadian tacrolimus versus microemulsion cyclosporin a trial: 1‐year follow‐up

  2003cited by this paper
• Single-dose daclizumab induction therapy in patients with liver transplantation.

  2003cited by this paper
• A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation.

  2002cited by this paper
• Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial.

  2002cited by this paper
• Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study.

  2002cited by this paper
• Cardiovascular morbidity and mortality after orthotopic liver transplantation.

  2002cited by this paper
• First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV.

  2002cited by this paper
• Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double‐blind randomized placebo‐controlled trial

  2002cited by this paper
• Liver transplant induction trial of daclizumab to spare calcineurin inhibition.

  2002cited by this paper
• Long‐term Safety, Tolerability and Efficacy of Daclizumab (Zenapax®) in a Two‐dose Regimen in Liver Transplant Recipients

  2002cited by this paper
• Safety and risk of using pediatric donor livers in adult liver transplantation

  2001cited by this paper
• A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

  2001cited by this paper
• Long‐term management of the liver transplant patient: Diabetes, hyperlipidemia, and obesity

  2001cited by this paper
• Liver transplantation using sirolimus and minimal corticosteroids (3‐day taper)

  2001cited by this paper
• Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study.

  2001cited by this paper
• Daclizumab induction therapy in combination with tacrolimus.

  2001cited by this paper
• A NOVEL MANAGEMENT STRATEGY OF STEROID-FREE IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION: EFFICACY AND SAFETY OF TACROLIMUS AND MYCOPHENOLATE MOFETIL

  2001cited by this paper
• A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.

  2001cited by this paper
• Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.

  2001cited by this paper
• Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function

  2001cited by this paper
• Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.

  2000cited by this paper
• Steroid withdrawal in liver transplantation: benefits, risks, and unanswered questions.

  2000cited by this paper
• A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin.

  1999cited by this paper
• The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients.

  1999cited by this paper
• A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation.

  1999cited by this paper
• Early steroid withdrawal in liver transplantation is safe and beneficial.

  1999cited by this paper
• Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients.

  1998cited by this paper
• Early cyclosporine monotherapy in liver transplantation: A 5‐year follow‐up of a prospective, randomized trial

  1998cited by this paper
• Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

  1997cited by this paper
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients

  1997cited by this paper
• Banff schema for grading liver allograft rejection: An international consensus document

  1997cited by this paper
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

  1997cited by this paper
• Maintenance immunosuppression using cyclosporine monotherapy in adult orthotopic liver transplant recipients.

  1996cited by this paper
• Corticosteroid withdrawal after liver transplantation.

  1995cited by this paper
• The IL-2 receptor complex: its structure, function, and target genes.

  1993cited by this paper
• A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

  1991cited by this paper
• Maintenance immunosuppression without steroids in pediatric liver transplantation.

  1989cited by this paper
• A humanized antibody that binds to the interleukin 2 receptor.

  1989cited by this paper

• Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials

  2014cites this paper
• Induction Immunosuppressive Therapy

  2014cites this paper
• Antibody induction versus corticosteroid induction for liver transplant recipients.

  2014cites this paper
• A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

  2013cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant

  2010cites this paper
• Liver Transplantation: Prevention and Treatment of Rejection

  2010cites this paper
• Liver transplant: a primer.

  2010cites this paper
• Antibody immunosuppressive therapy in solid organ transplant

  2010cites this paper
• 42. Liver Transplantation: Prevention and Treatment of Rejection

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant: Part I.

  2010cites this paper
• A clinical assessment of mycophenolate drug monitoring after liver transplantation

  2010cites this paper
• Mycophenolate mofetil: An update.

  2009cites this paper
• Minimization of steroids in liver transplantation

  2009cites this paper
• A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids

  2009cites this paper
• Capítulo 15 – Inmunosupresión en el trasplante hepático

  2008cites this paper
• Predictive Factors for Posttransplant Diabetes Mellitus Within One-Year of Liver Transplantation

  2008cites this paper
• Capítulo 19 – Rechazo agudo

  2008cites this paper
• Fortschritte in der Immunsuppression

  2008cites this paper
• [Progress in immunosuppression].

  2008cites this paper
• Patient Outcomes in Two Steroid-Free Regimens Using Tacrolimus Monotherapy After Daclizumab Induction and Tacrolimus With Mycophenolate Mofetil in Liver Transplantation

  2008cites this paper
• Tacrolimus Monotherapy in Liver Transplantation: One-Year Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Study

  2008cites this paper
• High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.

  2008cites this paper
• Klinik und Poliklinik für Hepatobiliäre Chirurgie und Transplantationschirurgie des Universitätsklinikums Hamburg-Eppendorf

  2008cites this paper
• Prevention of diabetes: effect of mycophenolate mofetil and anti‐CD25 on onset of diabetes in the DRBB rat

  2008cites this paper
• Daclizumab

  2007cites this paper
• Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation.

  2007cites this paper
• Current World Literature

  2007cites this paper
• New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation?

  2007cites this paper
• The role of antibody induction in liver transplantation

  2007cites this paper
• Current World Literature

  2006cites this paper